Psychedelic Inspired Medicines(TM) MindMed discov

Psychedelic Inspired Medicines(TM)
MindMed discovers, develops and deploys psychedelic inspired medicines to alleviate suffering and improve health.
******************************************************************************************************
MindMed now has a pipline of psychedelic insirped medicines.
All drug trials are to be through human clinical trials under the eye of the Federal regulatory authorities such as the FDA
******************************************************************************************************
There are two classification for their Medications
1. Non-Hallucinogenics Medicines
-Derived from psychedilics, zero to negligible hallucination effect
-Doctor prescription
-Pharmacy pickup, take home

2. Hallucinogenic Therapies
-A dose of generic psychedelics which causes a hallucinogenic experience
-Direct supervision by therapists & doctor
-In-clinic treatment only
******************************************************************************************************
Acquired Exclusive License to Clinical Trials of LSD- Partners with Psychedelic Research Laboratory at UNiversity Hospital Basel.
The multi-year deal gives access to a large collection of Clinical trials & Knowhow for LSD psychedelic research including a Phase 2 clincal trial for the treatment of anxiety.
The Lab belongs to Professor Dr. Matthias Liechti
Clinical Trial Pipeline
MindMed has and is building a IP portfolio and undertaking clinical trials of medicines based on psychedelics.
The pipline will also grow though acquisitions, joint ventures, and collaborative development agreement.
1. LSD Micro-dosing - Preparing Phase II clinical Trial (ADHD)
A growing trend in silicon valley is to take small amounts of LSD with no hallucination effects to increase focus and creativity. MindMed is undertaking clinical trials to prove it actually works.

2. 18-MC (Derived from Ibogaine) - Preparing Phase II FDA clinical Trials (opioid ise Disorder)
At present, 11 Million Americans are misusing opioids. MindMed is developing an anti-addictive molecule based on Ibogaine that treats addication as a brain disease.

Outstanding Shares
201,271,251
04/23/2020
=============================================================================================================

https://www.otcmarkets.com/stock/MMEDF/disclosure

https://www.otcmarkets.com/stock/MMEDF/news

https://www.otcmarkets.com/stock/MMEDF/security ;

https://www.otcmarkets.com/stock/MMEDF/profile

https://www.otcmarkets.com/stock/MMEDF/quote ;

https://www.otcmarkets.com/stock/MMEDF/overview